Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00133042 · ClinicalTrials.gov registry record · Phase 4
The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled Asthma
A Phase 4 study of Asthma, sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT00133042 is a Phase 4 study of Asthma that has completed, run by University of Florida. The registered enrollment target is 16 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00133042, a Phase 4 study of Asthma, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether the addition of omalizumab in patients with poorly controlled asthma (because of poor adherence) will decrease allergic airway inflammation and improve asthma control.
Conditions Studied
Interventions
- DRUG omalizumab
Study Locations (1)
Florida
- University of Florida Asthma Research Lab - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00133042
The ClinicalTrials.gov registry entry for NCT00133042 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (99% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which omalizumab is the first listed.
NCT00133042 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00133042 about?
NCT00133042 is a clinical study titled "The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled Asthma". The purpose of this study is to determine whether the addition of omalizumab in patients with poorly controlled asthma (because of poor adherence) will decrease allergic airway inflammation and improve asthma control.
What is the current status of trial NCT00133042?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2004-12. Estimated completion is 2006-12.
What conditions does trial NCT00133042 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00133042?
The interventions under investigation include: omalizumab (DRUG).
Who is sponsoring clinical trial NCT00133042?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00133042 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.